ESTRO 2024 - Abstract Book

S262

Brachytherapy - Gynaecology

ESTRO 2024

small bowel, while rectal doses were similar between the two applicators. The dose coverage in form of EQD2 HR CTV D50, D90 and D98 is similar for both applicators. Significantly more patients treated with Syed brachytherapy had no acute toxicities compared to those treated with T&O brachytherapy.

Keywords: Brachytherapy, T & O Applicator, Syed Applicator

References:

Potter, R., K. Tanderup, M. P. Schmid, I. Jurgenliemk-Schulz, C. Haie-Meder, L. U. Fokdal, A. E. Sturdza, P. Hoskin, U. Mahantshetty, B. Segedin, K. Bruheim, F. Huang, B. Rai, R. Cooper, E. van der Steen-Banasik, E. Van Limbergen, B. R. Pieters, L. T. Tan, R. A. Nout, A. A. C. De Leeuw, R. Ristl, P. Petric, N. Nesvacil, K. Kirchheiner, C. Kirisits, J. C. Lindegaard and E. C. Group (2021). "MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study." Lancet Oncol 22(4): 538-547. Otter, S., A. Coates, A. Franklin, M. Cunningham and A. Stewart (2018). "Improving dose delivery by adding interstitial catheters to fixed geometry applicators in high-dose-rate brachytherapy for cervical cancer." Brachytherapy 17(3): 580-586.

2112

Poster Discussion

Morbidity related to radiotherapy and T-score:prognostic factors in locally advanced cervical cancer

Sofia Córdoba Largo, Beatriz Gil Haro, Sofía Santana Jiménez, Cristina de la Fuente Alonso, Marta López Valcárcel, Raquel Benlloch Rodríguez, María Hernández Miguel, Irma Zapata Paz, Joaquín Velasco, María Angeles ruiz Rodríguez, Sara Perez Mata, Francisco Javier Martínez Paredes, Jesús Romero Fernández

Puerta de Hierro Hospital, Radiation Oncology, Madrid, Spain

Purpose/Objective:

To assess dosimetric factors predicting rectal and urinary morbidity and describe vaginal toxicity in patients treated with chemoradiation (CRT) and image-guide brachytherapy (IGBT-MRI) for locally advanced cervical cancer.

Material/Methods:

From November 2019 to Marzo 2023 we treated 51 patients (p) with stages IB-IV cervical carcinoma. Mean age: 55 years (32-87). TNM stage: IB: 3p, II: 13p, III: 33p and IV: 2p. Histology: epidermoid: 44p; adenocarcinoma: 7p. Human papillomavirus (HPV) was assessed in 40p (31p with epidermoid carcinoma HPV-dependent and 5p with adenocarcinoma HPV-dependent). All patients were treated with CRT and 3D-based planning intracavitary/interstitial IGBT, using the GEC-ESTRO recommendations for defining high-risk clinical target volume (HR-CTV). The involvement of 8 anatomical locations (cervix, left parametrium, right parametrium, vagina, bladder, ureter, rectum and uterine body) was scored according to an ordinal scale from 0 to 3 points. The total sum of points constituted the T-score. Equieffective doses at 2Gy (EQD2) were calculated, applying linear quadratic model. Toxicity was evaluated according to CTCAE v.5.0 criteria.